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Simple Summary: This prospective study investigated the prevalence, molecular characteristics
and risk factors of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E)
shedding in three equine cohorts: (i) farm horses (13 farms, n = 192); (ii) on admission to a hospital
(n = 168) and; (iii) horses hospitalized for ≥72 h re-sampled from cohort (ii) (n = 86). Bacteria were
isolated from rectal swabs, identified, antibiotic susceptibility patterns were determined, and medical
records and owners’ questionnaires were analyzed for risk factor analysis. ESBL shedding rates
significantly increased during hospitalization (77.9%, n = 67/86), compared to farms (20.8%, n =
40/192), and horses on admission (19.6%, n = 33/168). High bacterial species diversity was identified,
mainly in cohorts (ii) and (iii), with high resistance rates to commonly used antimicrobials. Risk
factors for shedding in farms included horses’ breed (Arabian), sex (stallion), and antibiotic treatment.
Older age was identified as a protective factor. We demonstrated a reservoir for antibiotic-resistant
bacteria in an equine hospital and farms, with a significant ESBL-E acquisition. In light of our findings,
in order to control ESBL spread, we recommend conducting active ESBL surveillance programs
alongside antibiotic stewardship programs in equine facilities.
Abstract: We aimed to investigate the prevalence, molecular characteristics and risk factors of
extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) shedding in horses.
A prospective study included three cohorts: (i) farm horses (13 farms, n = 192); (ii) on hospital
admission (n = 168) and; (iii) horses hospitalized for ≥72 h re-sampled from cohort (ii) (n = 86).
Enriched rectal swabs were plated, ESBL-production was confirmed (Clinical and Laboratory
Standards Institute (CLSI)) and genes were identified (polymerase chain reaction (PCR)). Identification
and antibiotic susceptibility were determined (Vitek-2). Medical records and owners’ questionnaires
were analyzed. Shedding rates increased from 19.6% (n = 33/168) on admission to 77.9% (n = 67/86)
during hospitalization (p < 0.0001, odds ratio (OR) = 12.12). Shedding rate in farms was 20.8%
(n = 40/192), significantly lower compared to hospitalized horses (p < 0.0001). The main ESBL-E species
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(n = 192 isolates) were E. coli (59.9%, 115/192), Enterobacter sp. (17.7%, 34/192) and Klebsiella pneumoniae
(13.0%, 25/192). The main gene group was CTX-M-1 (56.8%). A significant increase in resistance rates
to chloramphenicol, enrofloxacin, gentamicin, nitrofurantoin, and trimethoprim-sulpha was identified
during hospitalization. Risk factors for shedding in farms included breed (Arabian, OR = 3.9), sex
(stallion, OR = 3.4), and antibiotic treatment (OR = 9.8). Older age was identified as a protective
factor (OR = 0.88). We demonstrated an ESBL-E reservoir in equine cohorts, with a significant
ESBL-E acquisition, which increases the necessity to implement active surveillance and antibiotic
stewardship programs.
Keywords: equine; ESBL-E; antibiotic resistance; shedding; risk factors; farm; ESBL-E acquisition
1. Introduction
Extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae (ESBL-E) poses a clinical
challenge to both human and veterinary clinicians. ESBLs confer resistance to penicillins,
cephalosporins, and aztreonam and are often accompanied by fluoroquinolone resistance, which even
further narrows antibiotic treatment options [1]. Moreover, many ESBL genes are encoded on large
plasmids, which enables lateral transfer between different bacterial species, within the same host
and between different hosts [2]. In human medicine, ESBL production is associated with increased
morbidity, higher overall and infection-related mortality, increased hospital length of stay, delay of
targeted appropriate treatment, and higher costs [3,4]. Risk factors for colonization and infection in
humans include severe illness with prolonged hospital stays, the presence of invasive medical devices
for a prolonged duration and antibiotic use [2].
Within the last decade, a growing burden of ESBL-E in companion animals is being observed,
both as gut colonizing bacteria and as infecting pathogens, causing wounds, respiratory, urogenital,
gastro-intestinal, umbilical infections, and bacteremia [5–8]. Horses were described as carriers, as well
as infected by ESBL-E, in equine clinics and in farm settings [9,10]. Prevalence of ESBL-producing E. coli
carriage in horses varies between 4–44% in different European countries [11–13], with a lower carriage
prevalence in equine riding centers in comparison with equine clinics [10]. In equine community
settings, being stabled in the same yard with a recently hospitalized horse was identified as a risk
factor for ESBL-producing E. coli carriage [14]. Risk factor analysis in the level of the farm revealed that
the odds of being an ESBL/AmpC-producing E. coli premises were higher among riding schools than
breeding premises, if premises housed a horse that had been medically treated with antibiotics within
the last three months, and also in premises where the staff consisted of more than five persons [13].
However, risk factors for shedding of different ESBL-E species within horses were not yet reported.
We aimed to investigate and compare ESBL-E shedding in different equine cohorts, including farm
horses, horses on admission to an equine hospital and during hospitalization, as well as to determine
risk factors for shedding. We hypothesized that shedding rates increase during hospitalization,
that previous antibiotic treatment is a risk factor for shedding and that shedding on admission and
during hospitalization is associated with clinical signs, prolonged hospitalization, and severe outcome.
2. Materials and Methods
2.1. Equine Study Cohorts, Study Design, and Sampling Methods
This prospective study was performed on 13 farms throughout Israel and in the Koret School of
Veterinary Medicine—Veterinary Teaching Hospital (KSVM-VTH). The study was approved by the
Internal Research Review Committee of the KSVM-VTH (Reference numbers: KSVM-VTH/15_2015,
KSVM-VTH/23_2015). Rectal swabs were collected from the horses with owner consent. On admission,
sampling was performed prior to any medical treatment in the hospital. When horses survived and
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were not discharged, a second sample was taken 72 h post-admission. Farm horses were located in
different regions of Israel to roughly represent the population.
2.2. Demographic and Medical Data
For farm horses (cohort (i)), owners’ questionnaires were reviewed for data regarding individual
horses, including the originating farm, signalment (age, sex, and breed), duration of the horse’s
accommodation in the farm, hospitalization and antibiotic treatments within the previous year.
For hospitalized horses (cohort (ii)), medical records were reviewed for the following information:
signalment (age, sex, and breed), geographic origin, previous admission to the hospital within the
previous year (yes/no), clinical signs, duration of illness before admission, antibiotic therapy before
and during hospitalization, surgical procedures, other medications, hospitalization length, short-term
outcome, and admission charge.
2.3. ESBL-E Isolation and Species Identification
Rectal specimens [14] were collected using bacteriological swabs (Meus s.r.l., Piove di Sacco, Italy)
and were inoculated directly into a Luria Bertani infusion enrichment broth (Hy-Labs, Rehovot, Israel)
to increase the sensitivity of ESBL-E detection [15]. After incubation at 37 ◦C (18–24 h), enriched
samples were plated onto Chromagar ESBL plates (Hy-Labs, Rehovot, Israel), at 37 ◦C for 24 h. Colonies
that appeared after overnight incubation at 37 ◦C were recorded, and one colony of each distinct color
was re-streaked onto a fresh Chromagar ESBL plate to obtain a pure culture. Pure isolates were stored
at −80 ◦C for further analysis.
Isolates were subjected to Vitek-MS (BioMérieux, Inc., Marcy-l’Etoile, France) for species
identification or to Vitek-2 (BioMérieux, Inc., Marcy-l’Etoile, France) for species identification and/or
antibiotic susceptibility testing (AST-N270 Vitek 2 card). Chloramphenicol, enrofloxacin, and imipenem
were analyzed using disc diffusion assay (Oxoid, Basingstoke, UK). ESBL-production was confirmed by
combination disk diffusion using cefotaxime and ceftazidime discs (Oxoid, Basingstoke, UK), as well
as cefotaxime and ceftazidime with clavulanic acid (Sensi-Discs BD, Breda, The Netherlands). Results
were interpreted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines [16].
Multidrug-resistant (MDR) bacteria were defined as such due to their in vitro resistance to three or
more classes of antimicrobial agents [17].
2.4. Molecular Characterization of ESBL-E
Isolates were examined for the presence of the blaCTX-M group using a multiplex polymerase
chain reaction (PCR) from ESBL-E DNA lysates, as previously described [18]. Isolates that were
found to be blaCTX-M PCR negative were further examined for the presence of blaOXA-1, blaOXA2,
blaOXA10 [19], blaTEM, and blaSHV groups [20]. ESBL-producing E. coli isolates were subjected to
PCR for the detection of mdh and gyrB genes in order to determine the presence of the worldwide
pandemic E. coli ST131 lineage [21].
2.5. Sample Size and Statistical Analysis
The minimal sample size (number of animals sampled) for farm horses was calculated using
WinPepi, based on an estimated shedding rate of 25% for ESBL-E in equine community livery
premises [22] and on the fact that Israel is endemic for ESBL-E [23], with a confidence level of 95% and
an acceptable difference of 7%, resulting in n = 147.
The minimal sample size for horses on admission to hospital was based on the expected difference
between ESBL-E shedding and non-shedding horses and the percentage of admitted horses that were
treated with antibiotics before admission since antibiotic treatment was assumed to be a risk factor
for shedding [12]. Since there is no previous study revealing percentages of antibiotic-treated horses
and ESBL shedding, data for this calculation was based on a human study [24]. Estimating that
25% of horses on admission are ESBL shedders (representing the equine community) and that 72%
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and 44% of horses were treated with antimicrobials within shedders and non-shedders, respectively,
with a 5% significance level and power of 80%, the total required sample size is 145 horses, including
116 non-shedders and 29 shedders.
Risk assessment was performed using Chi-square or Fisher’s exact tests for association between
individual variables, shedding and ESBL-E acquisition. Descriptive statistics were used to describe
shedding rates. Continuous variables were analyzed using t-tests or Mann–Whitney U-tests. p ≤ 0.05
was considered statistically significant. For risk factor analysis of farm horses, a logistic regression
model (multivariable analysis) was conducted using all the significant variables in the univariable
analysis at a significance level of p < 0.2 using the ENTER method (IBM SPSS Statistics 25). Categorical
data were summarized by the number of cases (percentage) and confidence intervals (95%) were
calculated by Fisher’s (WinPEPI 11.15 Describe A).
In order to compare between shedding rates and antibiotic resistance rates within horses on admission
and during hospitalization (cohorts (ii) and (iii), respectively), a mixed effect logistic regression model was
conducted (STATA version 13). Resistance was defined as complete resistance (not including “intermediate
resistance”). Odds ratio (OR) for a significant change in antibiotic resistance rates is defined as OR
for a change in one resistance category (e.g., a change from “susceptible” to “intermediate” or from
“intermediate” to “resistant”). A comparison between shedding rates and antibiotic resistance rates
between farm horses (cohort (i)) and horses on admission (cohort (ii)) was performed using Chi-square.
3. Results
3.1. Characterization of the Equine Study Populations (Table 1)
Overall, 192 horses were sampled, originating from 13 farms across Israel (June 2016–September
2018). The average number of sampled horses per farm was 15 (range: 3–26 horses).
On admission, 168 horses were sampled (November 2015 to April 2016). Horses were admitted to
hospitalization due to the following reasons: gastro-intestinal pathologies (33%, n = 55/168), orthopedic
disorders (17%, n = 29/168), healthy (mares of sick neonatal foals or foals of sick mares, 17%, n = 29/168),
reproduction disorders (12%, n = 20/168), neonatology disorders (12%, n = 20/168), respiratory disorders
(4%, n = 7/168), and others (including ophthalmic, hematology, endocrine, teeth disorders, and tumors,
5%, n = 8/168). The median length of illness before admission was one day (range: several hours–750 d).
Horses hospitalized for ≥72 h were re-sampled (n = 86).
Table 1. Characterization of farm horses versus horses on admission to hospital.
Equine Cohort Breeds 1 Median Age 2 (Years ± SD) Sex Distribution 3
Farm horses (n = 192)
41.1% Arabians (n = 79/192)
25% pacers (n = 48/192)
15.1% Quarter horses (n = 29/192)
9.9% Warmbloods (n = 19/192)
5.2% local breed (n = 10/192)
3.7% ponies (n = 7/192)
8 ± 5.3
mares (72.4%, n = 139/192)
geldings (12.5%, n = 24/192)
stallions (11.5%, n = 22/192) 4
Horses on admission
(n = 168)
49.4% Arabians (n = 83/168)
19.6% Quarter horses (n = 33/168)
14.3% pacers (n = 24/168)
7.7% Friesians (n = 13/168)
4.8% Warmbloods (n = 8/168)
4.2% others (n = 7/168)
4.5 ± 5.2
mares (68.5%, n = 115/168)
geldings (16.1%, n = 27/168)
stallions (15.4%, n = 26/168)
1 Breed distribution was not significantly different for Arabians, Quarter horses, and Warmbloods in comparison
to farm horses, and was significantly different for the pacers horses (significantly higher in farms, p = 0.012) and
Friesians (significantly higher on admission, p < 0.001); 2 Median age of horses on admission was significantly lower
than the median age of farm horses (p < 0.0001); 3 Sex distribution was not significantly different between farm
horses and horses on admission; 4 Data was not available for seven horses.
3.2. Antibiotic Therapy, Surgical Procedures, Length of Stay, and Outcome
A proportion of 8.3% (n = 16/192) of farm horses was hospitalized within the previous year, ranging
from 0–30% between farms. A proportion of 19.8% (n = 38/192) of horses were treated with antibiotics
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within the previous year, ranging from 0–61% between farms. On admission, 9.5% (n = 16/168) of
horses were reported to be previously hospitalized (within a year period), and 16.1% (n = 27/168) of
horses were treated with antibiotics within the previous year. Previous hospitalization and antibiotic
treatment prevalence rates were not significantly different in comparison with farm horses.
During hospitalization, 50.6% of horses (n = 85/168) were treated with antibiotics, a proportion
which is significantly higher than antibiotic treatment in farms and prior to admission (p < 0.0001).
Surgical procedures were performed in 36.9% of horses (n = 62/168). The median length of stay was
three days (range: several hours-21 d). Out of all horses admitted to hospitalization, 84.4% survived to
discharge (n = 142/168).
3.3. Prevalence of ESBL-E Shedding
Within farm horses, shedding rate was 20.8% [n = 40/192, 95% Confidence interval (CI) 15.3–27.3%,
Table 1]. Shedding rate on admission was 19.6% (n = 33/168, 95% CI: 13.9–26.5%), which was not
statistically different from shedding rate in farms (p = 0.79). Shedding rate of hospitalized horses
(re-sampled) was 77.9% (n = 67/86, 95% CI 67.7–86.1%), which was significantly higher than the shedding
rate on admission and in farms (p<0.001, OR = 12.12, 95% CI 3.92–37.49). Out of 67 hospitalized
shedding horses, 77.6% (n = 52/67, 95% CI 65.8–86.9%) did not shed ESBL-E on admission.
3.4. Distribution of ESBL-E Species and ESBL Genes
Overall, 192 ESBL-E isolates were analyzed (Table A1). Fourteen bacterial species were identified
of which three were identified in all cohorts—E. coli, Klebsiella pneumoniae, and Enterobacter cloacae
(Figure 1). The most prevalent bacterial species in all cohorts was E. coli, consisting of 79.2% of isolates
from farms, 66.7% from horses on admission, and 49.0% from hospitalized horses. However, the
prevalence of E. coli decreased in horses on admission and in hospitalized horses, as the diversity of
other ESBL-E species increased, from four species in farms to five species on admission and twelve
species in hospitalized horses. Nosocomial ESBL-E species that were not identified in farms and on
admission included Citrobacter freundii (n = 3/105), Salmonella spp (n = 3/105), K. oxytoca, Citrobacter brakii,
E. vulneris, Pantoea spp, Proteus mirabilis, and Raoultella ornithinolytica (n = 1/105 each). The pandemic
hypervirulent E. coli ST131 [25] was identified in three horses: two horses on admission and one horse
during hospitalization. The main ESBL gene was the blaCTX-M-1 group in all cohorts (total 56.8% of
all isolates, Table 2).
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Figure 1. ESBL-E species distribution isolated from cohort (i) farm horses ((A), n = 48 isolates), cohort
(ii) horses on admission to the hospital ((B), n = 39 isolates) and cohort (iii) 72 h post-admission ((C),
n = 105 isolates).
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Table 2. Shedding rates of extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) in
farm horses, on admission, and during hospitalization.
Equine Cohort Shedding (%) Total No. ofESBL-E Isolates MDR Isolates (%) blaESBL Gene Group (%)
















(72 h post admission) 1
67/86 (77.9) 2
(95% CI 67.7–86.1%)








1 Horses re-sampled from cohort “horses on admission”; 2 Shedding rate in hospitalized horses is significantly
higher than shedding rate on admission and in farms (p < 0.0001, OR=12.12, 95% CI 3.92–37.49); 3 Prevalence of
multidrug-resistant (MDR) isolates is significantly higher in isolates originated from hospitalized horses compared
to isolates originated from horses on admission (p < 0.001).
3.5. Antibiotic Susceptibility Profiles
Antibiotic resistance rates varied between cohorts, with a significant increase during hospitalization.
All isolates from all cohorts were susceptible to imipenem (Table 3).
Table 3. Antibiotic 1 resistance rates (percentage) of ESBL-E isolates shed by farm horses, horses on
admission, and hospitalized horses.
Equine Cohort AMP AMC 2 LEX CAZ IMP CHL 3 ENR 4 AMK GEN 5 NIT 6 TMS 7
Farms 100 41.7 100 100 0 66.6 6.3 0 75 4.2 89.6
On admission 100 82.1 100 85.0 0 46.2 17.9 2.6 48.7 5.3 76.3
During
hospitalization 96.0 32.0 99.0 90.0 0 85.3 51.5 10.8 84.3 11.0 95.0
1 Abbreviations: ampicillin (AMP), amoxicillin-clavulanate (AMC), cephalexin (LEX), ceftazidime (CAZ), imipenem
(IMP), chloramphenicol (CHL), enrofloxacin (ENR), amikacin (AMK), gentamicin (GEN), nitrofurantoin (NIT), and
Trimethoprim- sulpha (TMS); 2 An increase in resistance rates for AMC on admission compared to farms (p = 0.001)
and a decrease during hospitalization compared to admission (p < 0.001, OR = 0.1, 95% CI 0.04, 0.26); 3 An increase
in resistance rates for CHL during hospitalization compared to admission (p < 0.001, OR = 6.5, 95% CI 2.8, 15); 4 An
increase in resistance rates for ENR during hospitalization compared to admission (p < 0.001, OR = 4.2, 95% CI 1.9,
9.5); 5 An increase in resistance rates for GEN during hospitalization compared to admission (p < 0.001, OR = 12.3,
95% CI 2.9, 52.5); 6 An increase in resistance rates for NIT during hospitalization compared to admission (p < 0.001,
OR = 3.7, 95% CI 1.4, 9.5); 7 An increase in resistance rates for TMS during hospitalization compared to admission
(p < 0.01, OR = 6, 95% CI 1.9, 19.4).
Among bacteria that grew on Chromagar ESBL plates, the prevalence of MDR bacteria was 89.6%,
71.8%, and 94.3% in farms, horses on admission, and hospitalized horses, respectively. The prevalence
rate was significantly higher in isolates originated from hospitalized horses compared to horses on
admission (p = 0.001, Table 2).
3.6. Risk Factor Analysis for ESBL-E Shedding
3.6.1. Farm Horses
In univariable analysis, horses’ breed, sex, hospitalization in the previous year, antibiotic treatment
in the previous year, and age were significantly associated with ESBL-E shedding (Table A2). Since the
Arabian breed was the most prevalent breed sampled, we clustered all other breeds as one category in
the multivariable analysis. In a logistic regression model, the breed (Arabian), sex (stallion versus mare,
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which was the reference in this category), and antibiotic treatment in the previous year were identified
as risk factors for shedding. Age greater than one year was identified as a protective factor (Table 4).
Table 4. Risk factor analysis for ESBL-E shedding by farm horses (logistic regression model).
Variable p-value Odds Ratio (95% CI)
Breed (Arabian versus non-Arabian) 0.006 3.9 (1.5–10.4)
Sex (reference: mare) 0.079 -
Stallion 0.029 3.4 (1.1–12.2)
Gelding 0.744 0.7 (0.07–6.4)
Age 0.008 0.9 (0.8–0.97)
Hospitalization within the previous year 0.194 2.9 (0.6–14.8)
Antibiotic treatment within the previous year <0.0001 9.8 (3.6–26.8)
3.6.2. Horses on Admission
Signalment (age, sex, and breed), geographic origin, prior hospitalizations in the last year, clinical
signs, length of illness before admission, antibiotic therapy before and during hospitalization, surgical
procedures, other medications, hospitalization length, short-term outcome, and admission charge
were not associated with ESBL-E shedding on admission (Table A2). Sex, hospitalization length,
and admission charge resulted in p < 0.2, therefore, were analyzed via a logistic regression model,
which did not yield any significant associations (Table A3).
3.6.3. Horses During Hospitalization
There was no association between ESBL shedding 72 h post-admission and on admission,
clinical signs on admission, antibiotic treatment during hospitalization, surgical procedures during
hospitalization, length of stay, admission charge and outcome (Table A2).
4. Discussion
This study investigates ESBL-E shedding in three equine cohorts, including farm horses,
representing community equine, as well as horses on admission to the hospital and during
hospitalization. Studies regarding antibiotic-resistant pathogens shedding, either in farm horses
or in hospitalized horses were reported previously from different European countries [13,22,26,27].
Our study compares different equine cohorts within the same country. Both community and hospital
cohorts are of great interest, from a veterinary and a ‘one health’ perspective, therefore it is highly
valuable to compare these cohorts.
We found high ESBL-E shedding rates (Table 2), an increased bacterial species diversity (Figure 1)
as well as in the ESBL-E genes variety (Table 2). An increase in shedding rates may be due to the
acquisition of bacteria, plasmids or resistance genes. The main bacterial species in all cohorts was
E. coli, with decreased incidence on admission and during hospitalization, due to increased incidence of
other nosocomial ESBL-producing bacterial species. The main ESBL gene group was CTX-M-1, as was
previously reported in community horses [26]. However, on admission and during hospitalization,
CTX-M-1 incidence decreases, alongside an increase in the number of ESBL genes. A study conducted
in an equine hospital in the UK demonstrated the emergence of ESBL-producing E. coli during a
decade [26], whereas we demonstrated a significant increase in ESBL-E shedding during individual
horses’ hospitalization. These findings support an urgent necessity in active surveillance and infection
control programs in veterinary facilities and hospitals.
In addition, there is a need to set strict antibiotic stewardship programs in veterinary medicine,
specifically in companion animals’ facilities, with specific guidance and enforcement. According to
a recommendation published by the Committee for Medicinal Products for Veterinary Use (CVMP)
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of the European Union, there is a need to reserve fluoroquinolones, third and fourth generation
cephalosporins for treatment when other options are likely to fail, and whenever possible, treatment
should be supported by an antimicrobial susceptibility testing [28]. In practice, fluoroquinolones
and cephalosporins are in use in equine medicine, sometimes as a first-line choice [29,30]. In our
study, ESBL-E shedding as well as resistance rates for chloramphenicol, enrofloxacin, gentamicin,
nitrofurantoin, and trimethoprim-sulpha increased significantly during hospitalization, resulting in a
significant increase in MDR bacterial species shedding (Tables 2 and 3). In light of our findings, as
well as increasing resistance rates in other equine studies, we recommend implementing antibiotic
stewardships in equine clinics and hospitals [31,32].
We also aimed to determine risk factors for shedding. We did not find significant associations
between shedding on admission and during hospitalization to medical data. During the study period,
we sampled all horses on admission, which represented a heterogeneous population, including critically
ill horses alongside healthy mares, which were hospitalized together with their sick foals. Therefore,
the lack of significant risk factors may be due to high variation in the equine population. Many of
the pathologies on admission were attributed to the gastro-intestinal system, which might influence
the intestinal microbiome. However, clinical signs on admission and during hospitalization were
not associated with shedding. In farm horses, we detected several risk factors for ESBL-E shedding
(Table 4). The Arabian breed was the main breed within farm horses and horses on admission to
hospital. These horses in Israel are used mainly for breeding and shows and are held under intensive
management, which may explain the risk for ESBL shedding. Interestingly, we detected the ‘stallion’
sex as a risk factor. In human medicine, it is reported that males are more susceptible to diverse
bacterial illnesses than females, including an ESBL-E infection [33], presumably related to hormonal
influences [34]. This may explain also our findings in veterinary medicine, however, it requires further
investigation. Previous antibiotic treatment was identified as a risk factor as well, in agreement with
other human and veterinary studies [2,13]. Age older than one year was identified as a protective
factor, which may be due to the maturation of immunity. In a national survey of cattle farms in Israel,
the prevalence of ESBL-E was higher in calves versus adult cows, where the use of antimicrobial
prophylaxis was more common [35]. In human medicine, elderly age is associated with ESBL-E
infections [33]. However, in our study, elderly horses older than 20 years old [36] were not prevalent
and consisted of 3% (n = 12/360) of the study population. Therefore, elderly age may not be identified
as a risk factor.
Our results should also be addressed from a ‘one health’ perspective. We detected resistant zoonotic
bacteria both in farms and in hospital settings, which underlines the necessity for awareness and
improved management. The human-animal interaction has great psychological and physical established
benefits, with a great emphasis on equine-assisted therapy [37–39]. Therefore, there is pronounced
importance in establishing safety policies involving therapists, physicians, and veterinarians, in order
to ensure safe human-equine interactions in community settings [40]. This also applies to veterinary
hospital staff. In a longitudinal study involving veterinary hospital staff and students, a higher level of
ESBL-producing E. coli carriage was observed longitudinally [41], which underlines the necessity to
implement gold standards biosecurity programs in veterinary hospitals.
5. Conclusions
Multi-drug resistant potentially zoonotic bacteria were detected both in farm horses and in
hospitalized horses, with a significantly increased shedding during hospitalization. Therefore,
we recommend implementing active surveillance programs alongside with infection control
and antibiotic stewardship policies, in order to decrease resistance burden and to allow safe
human-equine interactions.
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Appendix A
Table A1. Antimicrobial susceptibility profiles of individual isolates.
Num. Horse Serial Number Isolate Origin Bacterial ID AMC IMP ENR CHL GEN AMK TMS MDR
1 1 1.1.1
On admission
Escherichia coli 2 0 1 2 2 0 0 1
2 2 2.1.1 Escherichia coli 2 0 0 2 2 1 2 1
3 3 3.1.1 Escherichia coli 2 0 0 2 2 1 2 1
4 6 6.1.1 Citrobacter sedlakii 0 0 0 0 0 0 0 0
5 7 7.1.1 Klebsiella pneumoniae 2 0 1 2 2 0 2 1
6 15 15.1.1 Escherichia coli 2 0 1 2 2 1 2 1
7 15 15.1.2 Klebsiella pneumoniae 2 0 2 0 2 1 2 1
8 17 17.1.2 Klebsiella pneumoniae 2 0 1 0 0 0 2 1
9 22 22.1.1 Escherichia coli 2 0 0 2 2 1 2 1
10 22 22.1.2 Klebsiella pneumoniae 2 0 1 0 2 0 2 1
11 31 31.1.1 Escherichia coli 1 0 0 2 2 1 2 1
12 32 32.1.1 Escherichia coli 2 0 1 2 0 0 2 1
13 46 46.1.1 Enterobacter cloacae 2 0 0 0 0 0 0 0
14 60 60.1.1 Escherichia coli 2 0 1 0 0 0 2 1
15 74 74.1.2 Enterobacter cloacae 2 0 2 2 2 2 2 1
16 77 77.1.1 Escherichia coli 2 0 1 0 0 0 2 1
17 81 81.1.1 Escherichia coli 2 0 1 2 2 0 2 1
18 101 101.1.1 Escherichia coli 2 0 2 2 2 0 2 1
19 101 101.1.2 Klebsiella pneumoniae 2 0 1 0 0 0 2 0
20 107 107.1.1 Escherichia coli 2 0 1 0 0 0 2 1
21 112 112.1.1 Enterobacter cloacae 2 0 0 1 0 0 0 0
22 113 113.1.1 Escherichia coli 2 0 1 0 0 0 0 0
23 120 120.1.1 Escherichia coli 1 0 2 2 2 1 2 1
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Table A1. Cont.
Num. Horse Serial Number Isolate Origin Bacterial ID AMC IMP ENR CHL GEN AMK TMS MDR
24 121 121.1.1 Escherichia coli 2 1 2 2 0 0 0 1
25 136 136.1.1 Escherichia coli 2 0 2 2 0 0 2 1
26 136 136.1.2 Klebsiella pneumoniae 2 0 2 0 2 1 2 1
27 144 144.1.1 Escherichia coli 2 0 1 2 2 1 2 1
28 153 153.1.1 Escherichia coli 2 0 1 0 0 0 2 0
29 162 162.1.1 Escherichia coli 2 0 0 0 0 1 0 1
30 176 176.1.1 Escherichia coli 2 0 1 2 2 1 2 1
31 177 177.1.1 Escherichia coli 1 0 1 2 2 0 2 1
32 179 179.1.1 Escherichia coli 1 0 0 2 2 0 2 1
33 203 203.1.1 Klebsiella pneumoniae 0 0 0 0 2 0 0 0
34 239 239.1.1 Enterobacter cancerogenus 2 0 0 0 0 0 0 0
35 244 244.1.1 Citrobacter sedlakii 0 0 0 0 0 0
36 267 267.1.1 Escherichia coli 2 0 1 0 0 0 2 1
37 278 278.1.1 Escherichia coli 2 0 1 0 0 0 2 1
38 288 288.1.1 Escherichia coli 2 0 1 0 0 0 2 1




Klebsiella pneumoniae 0 0 1 0 2 0 2 1
41 5 5.2.1 Escherichia coli 0 0 0 2 2 0 2 1
42 6 6.2.1 Klebsiella pneumoniae 1 0 2 0 0 0 2 1
43 6 6.2.2 Escherichia coli 0 0 0 0 0 0 2 0
44 7 7.2.1 Escherichia coli 1 0 0 0 2 0 2 1
45 7 7.2.2 Klebsiella pneumoniae 1 0 2 2 2 0 2 1
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Table A1. Cont.
Num. Horse Serial Number Isolate Origin Bacterial ID AMC IMP ENR CHL GEN AMK TMS MDR
46 8 8.2.1 Escherichia coli 2 0 1 2 2 1
47 8 8.2.2 Enterobacter cloacae 2 0 2 2 2 0 2 1
48 15 15.2.1 Escherichia coli 1 0 2 2 2 0 2 1
49 15 15.2.2 Enterobacter cloacae 2 0 1 2 2 0 2 1
50 16 16.2.1 Escherichia coli 0 0 1 2 0 0 2 1
51 16 16.2.2 Enterobacter cloacae 2 0 2 2 2 0 2 1
52 29 29.2.1 Escherichia coli 1 0 2 2 2 0 2 1
53 29 29.2.2 Escherichia vulneris 0 0 1 2 2 0 2 1
54 31 31.2.1 Escherichia coli 1 0 2 2 2 0 2 1
55 35 35.2.1 Klebsiella pneumoniae 1 0 1 2 2 0 2 1
56 46 46.2.1 Pantoea spp 1 0 2 2 2 0 1
57 46 46.2.2 Escherichia coli 1 0 2 2 2 0 2 1
58 47 47.2.1 Escherichia coli 1 0 2 2 2 0 2 1
59 47 47.2.2 Enterobacter cloacae 2 0 2 2 2 2 2 1
60 49 49.2.2 Enterobacter cloacae 2 0 1 2 2 2 2 1
61 55 55.2.1 Escherichia coli 1 1 2 2 0 2 1
62 55 55.2.2 Klebsiella pneumoniae 1 0 2 0 2 0 2 1
63 56 56.2.2 Enterobacter cloacae 2 0 2 2 2 1 2 1
64 57 57.2.1 Escherichia coli 0 0 0 0 2 0
65 60 60.2.1 Enterobacter cloacae 2 0 2 2 2 0 2 1
66 60 60.2.3 Escherichia coli 1 0 1 2 2 0 2 1
67 72 72.2.3 Salmonella group 1 0 0 2 2 2 1
68 75 75.2.3 Enterobacter cloacae 2 0 1 2 2 0 2 1
69 84 84.2.1 Escherichia coli 0 0 0 2 2 0 2 1
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Table A1. Cont.
Num. Horse Serial Number Isolate Origin Bacterial ID AMC IMP ENR CHL GEN AMK TMS MDR
70 85 85.2.1 Escherichia coli 0 0 1 2 2 0 2 1
71 85 85.2.2 Enterobacter cloacae 2 0 2 2 2 0 2 1
72 87 87.2.1 Escherichia coli 0 0 2 2 0 0 2 1
73 87 87.2.2 Escherichia coli 1 0 2 2 2 0 2 1
74 89 89.2.1 Escherichia coli 1 0 2 2 2 0 2 1
75 89 89.2.2 Klebsiella pneumoniae 1 0 2 0 2 0 2 1
76 91 91.2.1 Escherichia coli 1 0 2 2 2 2 2 1
77 91 91.2.2 Enterobacter cloacae 2 0 2 2 2 0 2 1
78 101 101.2.1 Escherichia coli 1 0 2 2 1 0 2 1
79 101 101.2.2 Klebsiella pneumoniae 0 0 1 2 0 0 2 1
80 107 107.2.1 Escherichia coli 1 0 2 2 2 0 2 1
81 107 107.2.2 Enterobacter cloacae 2 0 2 2 2 2 2 1
82 107 107.2.4 Enterobacter cloacae 2 0 1 2 2 0 2 1
83 108 108.2.2 Enterobacter cloacae 2 0 1 2 2 0 2 1
84 113 113.2.1 Escherichia coli 2 2
85 115 115.2.1 Escherichia coli 0 0 2 2 2 0 2 1
86 115 115.2.2 Citrobacter freundii 2 0 2 2 2 0 2 1
87 124 124.2.1 Escherichia coli 0 0 2 2 2 0 2 1
88 124 124.2.3 Salmonella enterica 1 0 2 2 2 1
89 126 126.2.2 Citrobacter brakii 2 0 2 2 2 1 2 1
90 127 127.2.1 Escherichia coli 1 0 2 2 2 1 2 1
91 127 127.2.2 Enterobacter cloacae 2 0 1 2 2 0 2 1
92 136 136.2.1 Escherichia coli 1 0 2 2 2 1 2 1
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Num. Horse Serial Number Isolate Origin Bacterial ID AMC IMP ENR CHL GEN AMK TMS MDR
93 136 136.2.2 Klebsiella pneumoniae 1 0 2 0 2 0 2 1
94 143 143.2.1 Escherichia coli 0 0 0 2 2 0 2 1
95 143 143.2.2 Citrobacter freundii 2 0 0 2 2 0 2 1
96 144 144.2.1 Escherichia coli 2 0 1 2 2 0 2 1
97 144 144.2.2 Citrobacter freundii 2 0 2 1 2 1
98 144 144.2.3 Proteus mirabilis 1 0 2 0 0 1
99 148 148.2.1 Escherichia coli 2 0 0 0 0 0 2 1
100 149 149.2.1 Escherichia coli 0 0 0 2 2 0 2 1
101 149 149.2.2 Enterobacter cloacae 2 0 1 2 2 2 2 1
102 152 152.2.2 Escherichia coli 1 0 2 0 2 0 2 1
103 156 156.2.1 Enterobacter cloacae 2 0 1 2 2 2 2 1
104 156 156.2.2 Escherichia coli 1 0 2 2 2 0 2 1
105 158 158.2.2 Klebsiella pneumoniae 1 0 2 0 2 0 2 1
106 161 161.2.1 Escherichia coli 1 0 2 2 2 0 2 1
107 161 161.2.2 Enterobacter cloacae 2 0 1 2 2 0 2 1
108 167 167.2.1 Klebsiella pneumoniae 1 0 1 2 2 0 2 1
109 176 176.2.1 Escherichia coli 1 0 0 2 2 0 2 1
110 177 177.2.1 Escherichia coli 1 0 1 2 2 0 2 1
111 177 177.2.2 Enterobacter cloacae 2 0 1 2 2 0 2 1
112 181 181.2.1 Enterobacter cloacae 2 0 1 2 1 2 1
113 181 181.2.2 Escherichia coli 1 0 2 2 2 0 2 1
114 183 183.2.1 Klebsiella pneumoniae 1 0 1 2 2 0 2 1
115 183 183.2.2 Escherichia coli 1 0 0 2 2 0 2 1
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Table A1. Cont.
Num. Horse Serial Number Isolate Origin Bacterial ID AMC IMP ENR CHL GEN AMK TMS MDR
116 195 195.2.1 Escherichia coli 1 0 1 2 2 0 2 1
117 212 212.2.1 Escherichia coli 0 0 1 2 0 0 0
118 216 216.2.1 Escherichia coli 0 0 2 2 0 0 2 0
119 219 219.2.1 Escherichia coli 1 0 2 2 0 2 1
120 222 222.2.1 Klebsiella pneumoniae 1 0 1 2 2 0 2 1
121 222 222.2.2 Escherichia coli 0 0 2 2 0 0 2 1
122 223 223.2.1 Escherichia coli 1 0 2 2 2 0 0 1
123 224 224.2.1 Escherichia coli 1 0 2 2 2 0 2 1
124 224 224.2.2 Klebsiella pneumoniae 1 0 2 2 2 0 2 1
125 228 228.2.1 Klebsiella pneumoniae 0 0 2 0 2 0 0 1
126 229 229.2.1 Escherichia coli 1 0 2 2 2 2 2 1
127 229 229.2.2 Salmonella enterica 1 0 2 2 2 2 2 1
128 234 234.2.1 Raoultella ornithinolytica 2 0 1 2 2 2 2 1
129 237 237.2.1 Escherichia coli 0 0 0 2 0 0 2 1
130 238 238.2.1 Klebsiella pneumoniae 1 0 1 0 2 0 2 1
131 243 243.2.1 Escherichia coli 0 0 2 2 0 0 2 1
132 243 243.2.2 Enterobacter cloacae 2 0 1 2 2 0 2 1
133 246 246.2.1 Escherichia coli 1 0 1 0 2 1
134 246 246.2.2 Enterobacter cloacae 2 0 2 2 2 0 2 1
135 265 265.2.1 Enterobacter cloacae 2 0 1 2 2 0 2 1
136 272 272.2.1 Enterobacter cloacae 2 0 1 2 2 0 2 1
137 273 273.2.1 Enterobacter cloacae 2 0 1 2 2 0 2 1
138 278 278.2.1 Escherichia coli 0 0 1 2 0 0 2 1
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Num. Horse Serial Number Isolate Origin Bacterial ID AMC IMP ENR CHL GEN AMK TMS MDR
139 278 278.2.2 Citrobacter sedlakii 0 0 2 2 0 0 1
140 278 278.2.4 Klebsiella pneumoniae 0 0 2 2 2 0 0 1
141 279 279.2.1 Klebsiella oxytoca 2 0 0 0 2 1 2 1
142 279 279.2.2 Escherichia coli 0 0 1 2 0 0 2 1
143 289 289.2.1 Escherichia coli 1 0 2 0 2 0 2 1
144 H40 H40.2
Farms
Escherichia coli 2 0 1 0 0 0 2 1
145 H42 H42.1 Escherichia coli 2 0 1 2 2 1 2 1
146 H44 H44.1 Escherichia coli 2 0 1 2 2 1 2 1
147 H45 H45.2 Citrobacter farmeri 1 0 1 2 2 0 2 1
148 H48 H48.2 Escherichia coli 2 0 2 2 2 0 2 1
149 H48 H48.3 Enterobacter cloacae 2 0 1 2 2 1 2 1
150 H53 H53.1 Escherichia coli 2 0 1 0 0 0 2 1
151 H53 H53.2 Enterobacter cloacae 2 0 1 2 2 1 2 1
152 H54 H54.1 Escherichia coli 2 0 2 2 2 0 2 1
153 H56 H56.1 Escherichia coli 2 0 1 2 2 1 2 1
154 H56 H56.2 Enterobacter cloacae 2 0 1 2 2 1 2 1
155 H57 H57.1 Enterobacter cloacae 2 0 1 2 2 1 2 1
156 H57 H57.2 Escherichia coli 2 0 1 2 2 1 2 1
157 H60 H60.2 Escherichia coli 2 0 1 0 0 0 2 1
158 H110 H110.1 Enterobacter cloacae 2 0 0 0 0 0 0 0
159 H138 H138.1 Escherichia coli 2 0 0 0 0 0 0 1
160 H140 H140.1 Escherichia coli 2 0 0 2 2 1 2 1
161 H154 H154.2 Klebsiella pneumoniae 2 0 1 1 2 0 0 1
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Num. Horse Serial Number Isolate Origin Bacterial ID AMC IMP ENR CHL GEN AMK TMS MDR
162 H157 H157.2 Klebsiella pneumoniae 2 0 2 0 0 0 2 1
163 H230 H230.1 Escherichia coli 1 0 1 2 2 0 2 1
164 H230 H230.2 Enterobacter cloacae 2 0 1 2 2 0 0 1
165 H231 H231.1 Escherichia coli 0 0 1 0 0 0 0 0
166 H233 H233.1 Escherichia coli 1 0 1 2 2 0 2 1
168 H234 H234.1 Escherichia coli 0 0 1 2 2 0 2 1
169 H234 H234.2 Enterobacter cloacae 2 0 1 2 2 0 2 1
170 H235 H235.1 Escherichia coli 1 0 1 2 2 0 2 1
171 H236 H236.1 Escherichia coli 0 0 1 2 2 0 2 1
172 H237 H237.1 Escherichia coli 1 0 1 2 2 0 2 1
173 H238 H238.1 Escherichia coli 0 0 1 2 2 0 2 1
174 H241 H241.1 Escherichia coli 1 0 1 2 2 0 2 1
175 H242 H242.1 Escherichia coli 1 0 1 2 2 0 2 1
176 H243 H243.1 Escherichia coli 1 0 1 2 2 0 2 1
177 H245 H245.1 Escherichia coli 1 0 1 2 2 0 2 1
178 H246 H246.1 Escherichia coli 1 0 1 2 2 0 2 1
179 H247 H247.1 Escherichia coli 0 0 1 2 2 0 2 1
180 H248 H248.1 Escherichia coli 0 0 1 2 2 0 2 1
181 H250 H250.1 Escherichia coli 0 0 1 2 2 0 2 1
182 H251 H251.1 Escherichia coli 0 0 1 2 2 0 2 1
183 H253 H253.1 Escherichia coli 0 0 1 2 2 0 2 1
184 H254 H254.1 Escherichia coli 0 0 1 2 2 0 2 1
185 H256 H256.1 Escherichia coli 0 0 1 0 0 0 2 1
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Num. Horse Serial Number Isolate Origin Bacterial ID AMC IMP ENR CHL GEN AMK TMS MDR
186 H257 H257.1 Escherichia coli 1 0 0 1 2 0 2 1
187 H258 H258.1 Escherichia coli 0 0 0 0 0 0 2 0
188 H259 H259.1 Escherichia coli 0 0 0 0 0 0 2 0
189 H263 H263.1 Escherichia coli 0 0 0 0 0 0 2 0
190 H265 H265.1 Escherichia coli 1 0 0 1 2 0 2 1
191 H267 H267.1 Escherichia coli 0 0 1 0 0 0 2 1
192 H268 H268.1 Escherichia coli 1 0 0 1 2 0 2 1
Susceptible = 0, intermediate susceptibility = 1, resistant = 2. Empty cells mean lack of susceptibility test results due to technical reasons.
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Table A2. Results of univariable analysis of variables gleaned from the medical records (horses on
admission and during hospitalization) and owners’ questionnaires (farm horses). Variables were
evaluated for association with the outcome of ESBL-E shedding status of the individual animal.

















previous year Yes/No 0.018
Antibiotic treatment within the
previous year Yes/No <0.0001
Age Ranged from 0.1–23 y <0.0001





























previous year Yes/No 0.295









Healthy (mares of sick
hospitalized foals)
0.587
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Table A2. Cont.
Population Studied Variable Classification p-Value
Length of illness before
admission Days 0.618
Antibiotic treatment within the
previous year Yes/No 0.587
Length of stay Days 0.169
Admission charge - 0.056
During
hospitalization
Shedding on admission Yes/No 0.9

















Length of stay Days 0.29
Admission charge - 0.69
Table A3. Risk factor analysis for ESBL-E shedding by horses on admission to hospital (logistic
regression).
Risk Factor p-Value OR
Sex (reference: mare) 0.647
Stallion 0.409 0.571 (95% CI 0.151–2.162)
Gelding 0.639 0.765 (95% CI 0.25–2.34)
Length of stay 0.766 1 (95% CI 0.997–1)
Admission charge 0.184 1 (95% 1–1)
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